• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

    7.370 +1.170 (+18.87%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,035,777
    Open 6.430
    Bid (Size) 6.830 (300)
    Ask (Size) 7.000 (500)
    Prev. Close 6.200
    Today's Range 6.430 - 8.920
    52wk Range 4.930 - 114.00
    Shares Outstanding 620,290
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Penn State to Participate in Researching Potential Treatment for Pediatric Brain Cancer
    Via Investor Brand Network
    Preclinical Study Suggests Combo Therapy Could Treat Glioblastoma
    Via Investor Brand Network

    Performance

    YTD
    +39.1%
    +39.1%
    1 Month
    -0.3%
    -0.3%
    3 Month
    -22.3%
    -22.3%
    6 Month
    -31.5%
    -31.5%
    1 Year
    -88.7%
    -88.7%

    More News

    Read More
    Experts’ Views on Screen Time and Lifestyle on Pediatric Brain Tumors
    Via Investor Brand Network
    New Blood Test Reveals Whether Treatment is Working for Brain Cancer Patients
    Via Investor Brand Network
    MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals Announces CEO Transition
    Via ACCESS Newswire
    Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment
    Via Investor Brand Network
    Optimal Treatment Timing Could Boost Cancer Therapy Efficacy
    Via Investor Brand Network
    Nasal Drops Hold Promise in Fighting Deadly Brain Cancer
    Via Investor Brand Network
    MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast
    Via Investor Brand Network
    Common Drug for Blood Pressure Could Slow Glioblastoma
    Via Investor Brand Network
    BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs
    Via Investor Brand Network
    Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer
    Via Investor Brand Network
    Topics Death
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    New Implants Defy Necessity of Brain Surgery Against Cancer
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
    Via ACCESS Newswire
    Review Shows That Neurocognitive Functioning Declines in Patients with CNS Cancers
    Via Investor Brand Network
    What Patients Need to Know About the Remission Rate of Glioblastomas
    Via Investor Brand Network
    Scientists Uncover Possible Driver of ‘Chemo Brain’
    Via Investor Brand Network
    Virtual Brain Tumors Could Transform How Cancer is Treated
    Via Investor Brand Network
    New AI Tool Boosts Precision Medicine in Treating CNS Cancers
    Via Investor Brand Network
    Topics Artificial Intelligence
    Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue
    Via Investor Brand Network
    Scorpion Venom Shows Promise in Brain Tumor Treatment
    Via Investor Brand Network

    Frequently Asked Questions

    Is CNS Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, CNS Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does CNS Pharmaceuticals, Inc. - Common Stock trade on?
    CNS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock is CNSP on the Nasdaq Stock Market
    What is the current price of CNS Pharmaceuticals, Inc. - Common Stock?
    The current price of CNS Pharmaceuticals, Inc. - Common Stock is 7.370
    When was CNS Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of CNS Pharmaceuticals, Inc. - Common Stock was at 01/15/26 04:00 PM ET
    What is the market capitalization of CNS Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of CNS Pharmaceuticals, Inc. - Common Stock is 4.57M
    How many shares of CNS Pharmaceuticals, Inc. - Common Stock are outstanding?
    CNS Pharmaceuticals, Inc. - Common Stock has 5M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.